The evidence that the production of IFN-γ by CAR.CIK is stimulated by the interaction with the target TA supports the hypothesis that IFN-γ release occurring in patients after CAR.CIK infusion would be preferentially located at tumor sites, further limiting the risks of IFN-γ-associated systemic effects [41]. The gene discussed is IFNG; the disease is neoplasm.